292 related articles for article (PubMed ID: 37786592)
41. The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.
Baumfeld Andre E; Carrington N; Siami FS; Hiatt JC; McWilliams C; Hiller C; Surinach A; Zamorano A; Pashos CL; Schulz WL
Clin Pharmacol Ther; 2022 Dec; 112(6):1172-1182. PubMed ID: 35213741
[TBL] [Abstract][Full Text] [Related]
42. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
[TBL] [Abstract][Full Text] [Related]
43. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
[TBL] [Abstract][Full Text] [Related]
44. Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data.
Li Q; Lin J; Chi A; Davies S
Contemp Clin Trials; 2020 Oct; 97():106123. PubMed ID: 32853779
[TBL] [Abstract][Full Text] [Related]
45. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
[TBL] [Abstract][Full Text] [Related]
46. Real world evidence: An Indian perspective.
Dang A; Vallish BN
Perspect Clin Res; 2016; 7(4):156-160. PubMed ID: 27843789
[TBL] [Abstract][Full Text] [Related]
47. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
48. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms.
Beyrer J; Abedtash H; Hornbuckle K; Murray JF
J Comp Eff Res; 2022 May; 11(7):499-511. PubMed ID: 35296149
[No Abstract] [Full Text] [Related]
49. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
Klonoff DC
J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
[TBL] [Abstract][Full Text] [Related]
50. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
51. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
Li P; Wang S; Chen Y
Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
[TBL] [Abstract][Full Text] [Related]
52. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
[TBL] [Abstract][Full Text] [Related]
53. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
Saesen R; Van Hemelrijck M; Bogaerts J; Booth CM; Cornelissen JJ; Dekker A; Eisenhauer EA; Freitas A; Gronchi A; Hernán MA; Hulstaert F; Ost P; Szturz P; Verkooijen HM; Weller M; Wilson R; Lacombe D; van der Graaf WT
Eur J Cancer; 2023 Jun; 186():52-61. PubMed ID: 37030077
[TBL] [Abstract][Full Text] [Related]
54. Current status of real-world big data research in the cardiovascular field in Japan.
Tonegawa-Kuji R; Kanaoka K; Iwanaga Y
J Cardiol; 2023 Mar; 81(3):307-315. PubMed ID: 36126909
[TBL] [Abstract][Full Text] [Related]
55. Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers.
Magalhães T; Dinis-Oliveira RJ; Taveira-Gomes T
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886214
[TBL] [Abstract][Full Text] [Related]
56. Conducting real-world evidence studies in India.
Bhatt A
Perspect Clin Res; 2019; 10(2):51-56. PubMed ID: 31008069
[TBL] [Abstract][Full Text] [Related]
57. Use of Healthcare Claims Data to Generate Real-World Evidence on Patients With Drug-Resistant Epilepsy: Practical Considerations for Research.
Stamas N; Vincent T; Evans K; Li Q; Danielson V; Lassagne R; Berger A
J Health Econ Outcomes Res; 2024; 11(1):57-66. PubMed ID: 38425708
[No Abstract] [Full Text] [Related]
58. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
[TBL] [Abstract][Full Text] [Related]
59. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
Facey KM; Rannanheimo P; Batchelor L; Borchardt M; de Cock J
Int J Technol Assess Health Care; 2020 Sep; ():1-10. PubMed ID: 32878663
[TBL] [Abstract][Full Text] [Related]
60. The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies.
Lamberti MJ; Kubick W; Awatin J; McCormick J; Carroll J; Getz K
Ther Innov Regul Sci; 2018 Nov; 52(6):778-783. PubMed ID: 29714579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
